Cancer cachexia: Beyond weight loss

Journal of Oncology Practice

Volumn 12, Issue 11, 2016, Pages 1163-1171

  Bruggeman, Andrew R ^b   Kamal, Arif H ^b   LeBlanc, Thomas W ^b   Ma, Joseph D ^b   Baracos, Vickie E ^b   Roeland, Eric J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANNABINOID; CORTICOSTEROID; CYTOKINE; GESTAGEN; NEUROHORMONE;

BODY COMPOSITION; CACHEXIA; CANCER THERAPY; EXERCISE; FUNCTIONAL STATUS; HUMAN; NUTRITION; ONCOLOGIST; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; REVIEW; WEIGHT REDUCTION; COMPLICATION; NEOPLASMS;

BIOMARKERS; BODY COMPOSITION; CACHEXIA; EXERCISE; HUMANS; NEOPLASMS; WEIGHT LOSS;

EID: 85011629728     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2016.016832     Document Type: Review

References (46)

1. Fearon K, Strasser F, Anker SD, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 12:489-495, 2011
2. Martin L, Senesse P, Gioulbasanis I, et al:Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 33:90-99, 2015
3. Fearon KC, Glass DJ, Guttridge DC: Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab 16:153-166, 2012
4. Fearon KC, Voss AC, Hustead DS: Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345-1350, 2006
5. Ma JD, Heavey SF, Revta C, et al: Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther 14:1113-1120, 2014
6. LeBlanc TW, Nipp RD, Rushing CN, et al: Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. J Pain Symptom Manage 49:680-689, 2015
7. Prado CM, Lieffers JR, McCargar LJ, et al: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 9:629-635, 2008
8. Martin L, Birdsell L, Macdonald N, et al: Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539-1547, 2013
9. Shen W, Punyanitya M, Wang Z, et al: Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97:2333-2338, 2004
10. Hubbard JM, Cohen HJ, Muss HB: Incorporating biomarkers into cancer and aging research. J Clin Oncol 32:2611-2616, 2014
11. Popuri K, Cobzas D, Esfandiari N, et al: Body composition assessment in axial CT images using FEM-based automatic segmentation of skeletal muscle. IEEE Trans Med Imaging 35:512-520, 2016
12. Prado CM, Baracos VE, McCargar LJ, et al: Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13: 3264-3268, 2007
13. Barret M, Antoun S, Dalban C, et al: Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66:583-589, 2014
14. Prado CM, Baracos VE, McCargar LJ, et al: Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920-2926, 2009
15. Sjøblom B, Grønberg BH, Benth JŠ, et al: Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer 90:85-91, 2015
16. Yip C, Goh V, Davies A, et al: Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol 24:998-1005, 2014
17. Ali R, Baracos VE, Sawyer MB, et al: Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med 5:607-616, 2016
18. Tan BH, Deans DA, Skipworth RJ, et al: Biomarkers for cancer cachexia: Is there also a genetic component to cachexia? Support Care Cancer 16:229-234, 2008
19. Coussens LM, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002
20. Laird BJ, Fallon M, Hjermstad MJ, et al: Quality of life in patients with advanced cancer: Differential association with performance status and systemic inflammatory response. J Clin Oncol 34:2769-2775, 2016
21. Stephens NA, Skipworth RJ, Gallagher IJ, et al: Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle 6:53-61, 2015
22. Temel JS, Abernethy AP, Currow DC, et al: Anamorelin in patients with nonsmall-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519-531, 2016
23. Aoyagi T, Terracina KP, Raza A, et al: Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol 7:17-29, 2015
24. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, et al: Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev (3):CD004310, 2013
25. Loprinzi CL, Schaid DJ, Dose AM, et al: Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11:152-154, 1993
26. Loprinzi CL, Michalak JC, Schaid DJ, et al: Phase III evaluation of four doses of megestrol acetate as therapy for patientswith cancer anorexia and/or cachexia. J Clin Oncol 11:762-767, 1993
27. Strasser F, Luftner D, Possinger K, et al: Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancerrelated anorexia-cachexia syndrome: A multicenter, phase III, randomized, doubleblind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24:3394-3400, 2006
28. Struwe M, Kaempfer SH, Geiger CJ, et al: Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827-831, 1993
29. AbbVie: Marinol. 2016. http://www.marinol.com/
30. Loprinzi CL, Kugler JW, Sloan JA, et al: Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 17:3299-3306, 1999
31. Paulsen O, Klepstad P, Rosland JH, et al: Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: A randomized, placebo-controlled, double-blind trial. J Clin Oncol 32:3221-3228, 2014
32. Schäcke H, Döcke W-D, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23-43, 2002
33. Utech AE, Tadros EM, Hayes TG, et al: Predicting survival in cancer patients: The role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 3:245-251, 2012
34. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
35. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer, in MacLeod CM (ed): Evaluation of Chemotherapeutic Agents. New York, NY, Columbia University Press, 1949, pp 191-205
36. O'Keeffe ST, Lye M, Donnellan C, et al: Reproducibility and responsiveness of quality of life assessment and six minute walk test in elderly heart failure patients. Heart 80:377-382, 1998
37. MacDonald N, Easson AM, Mazurak VC, et al: Understanding and managing cancer cachexia. J Am Coll Surg 197:143-161, 2003
38. Wong GY, Schroeder DR, Carns PE, et al: Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: A randomized controlled trial. JAMA 291:1092-1099, 2004
39. Bakitas MA, Tosteson TD, Li Z, et al: Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33:1438-1445, 2015
40. Smith TJ, Temin S, Alesi ER, et al: American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care. J Clin Oncol 30:880-887, 2012
41. Baldwin C, Spiro A, Ahern R, et al: Oral nutritional interventions in malnourished patients with cancer: A systematic review and meta-analysis. J Natl Cancer Inst 104: 371-385, 2012
42. Ma YJ, Yu J, Xiao J, et al: The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: A systematic evaluation. Nutr Cancer 67:112-118, 2015
43. Gullett NP, Mazurak VC, Hebbar G, et al: Nutritional interventions for cancerinduced cachexia. Curr Probl Cancer 35:58-90, 2011
44. Stene GB, Helbostad JL, Balstad TR, et al: Effect of physical exercise on muscle mass and strength in cancer patients during treatment: A systematic review. Crit Rev Oncol Hematol 88:573-593, 2013
45. Oldervoll LM, Loge JH, Lydersen S, et al: Physical exercise for cancer patients with advanced disease: A randomized controlled trial. Oncologist 16:1649-1657, 2011
46. Grande AJ, Silva V, Maddocks M: Exercise for cancer cachexia in adults: Executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle 6:208-211, 2015